Literature DB >> 11689212

Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein.

V V Tertov1, V V Kaplun, I A Sobenin, E Y Boytsova, N V Bovin, A N Orekhov.   

Abstract

In earlier studies we have found that incubation of low density lipoprotein (LDL) with autologous blood plasma-derived serum leads to a loss of sialic acid from lipoprotein particles. In this study we demonstrated that sialic acid removed from LDL was transferred to glycoconjugates of lipoproteins, glycoproteins and sphingolipids of human serum. This showed that human serum contained the trans-sialidase activity. Gel-filtration chromatography of human blood serum demonstrated the presence of trans-sialidase activity in lipoprotein subfractions as well as in lipoprotein-deficient serum. Trans-sialidase (about 65 kDa) was isolated from lipoprotein-deficient serum using affinity chromatography carried out with Neu5Acalpha2-8Neu5Ac-sepharose FF-6. Optimal pH values for the trans-sialidase were 3.0, 5.0 and 7.0. Calcium and magnesium ions stimulated the enzyme activity at millimolar concentrations. Isolated enzyme can remove sialic acid from LDL, IDL, VLDL, and HDL particles (in decreasing rate order). Serum trans-sialidase transferred sialic acid from glycoconjugates of plasma proteins (fetuin, transferrin) and gangliosides (GM3, GD3, GM1, GD1a, GD1b). Sialylated glycoconjugates of human blood erythrocytes also served as substrate for serum trans-sialidase. We have found that sialic acid can also be removed from N- and O-linked glycans, sialylated Le(x) and Le(a), oligosialic acids, and sphingolipid carbohydrate chains. The rate of sialic acid release decreased in the following order: alpha2,6>alpha2,3>>alpha2,8. Transferred molecule of sialic acid can form alpha2,6, alpha2,3 and to a lesser degree alpha2,8 linkage with galactose, N-acetyl-galactosamine or sialic acid of acceptors. The glycoconjugates of erythrocytes, lipoprotein particles, plasma proteins, neutral sphingolipids and gangliosides may serve as acceptors of transferred sialic acid. Trans-sialidase-treated native LDL becomes desialylated and then can induce cholesteryl ester accumulation in human aortic intimal smooth muscle cells. Thus, trans-sialidase may be involved in the early stages of atherogenesis characterized by foam cell formation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689212     DOI: 10.1016/s0021-9150(01)00498-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  15 in total

Review 1.  Sialic acids in human health and disease.

Authors:  Ajit Varki
Journal:  Trends Mol Med       Date:  2008-07-06       Impact factor: 11.951

Review 2.  LDL electronegativity index: a potential novel index for predicting cardiovascular disease.

Authors:  Ekaterina A Ivanova; Yuri V Bobryshev; Alexander N Orekhov
Journal:  Vasc Health Risk Manag       Date:  2015-08-28

3.  Macrophages in immunopathology of atherosclerosis: a target for diagnostics and therapy.

Authors:  Alexander N Orekhov; Igor A Sobenin; Mikhail A Gavrilin; Alexei Gratchev; Svetlana Y Kotyashova; Nikita G Nikiforov; Julia Kzhyshkowska
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

4.  Reduced apolipoprotein glycosylation in patients with the metabolic syndrome.

Authors:  Olga V Savinova; Kristi Fillaus; Linhong Jing; William S Harris; Gregory C Shearer
Journal:  PLoS One       Date:  2014-08-12       Impact factor: 3.240

Review 5.  Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.

Authors:  Ekaterina A Ivanova; Veronika A Myasoedova; Alexandra A Melnichenko; Andrey V Grechko; Alexander N Orekhov
Journal:  Oxid Med Cell Longev       Date:  2017-05-07       Impact factor: 6.543

6.  Comparison of the Protective Effects of Individual Components of Particulated trans-Sialidase (PTCTS), PTC and TS, against High Cholesterol Diet-Induced Atherosclerosis in Rabbits.

Authors:  Shérrira M Garavelo; Maria de Lourdes Higuchi; Jaqueline J Pereira; Marcia M Reis; Joyce T Kawakami; Renata N Ikegami; Suely A P Palomino; Nilsa S Y Wadt; Abdelali Agouni
Journal:  Biomed Res Int       Date:  2017-02-27       Impact factor: 3.411

Review 7.  Proatherogenic Sialidases and Desialylated Lipoproteins: 35 Years of Research and Current State from Bench to Bedside.

Authors:  Alexandre Mezentsev; Evgeny Bezsonov; Dmitry Kashirskikh; Mirza S Baig; Ali H Eid; Alexander Orekhov
Journal:  Biomedicines       Date:  2021-05-25

8.  Approach to reduction of blood atherogenicity.

Authors:  Alexander N Orekhov; Alexandra A Melnichenko; Igor A Sobenin
Journal:  Oxid Med Cell Longev       Date:  2014-06-29       Impact factor: 6.543

Review 9.  Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.

Authors:  Alexander N Orekhov; Yuri V Bobryshev; Igor A Sobenin; Alexandra A Melnichenko; Dimitry A Chistiakov
Journal:  Int J Mol Sci       Date:  2014-07-21       Impact factor: 5.923

Review 10.  CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?

Authors:  Christian Abendstein Kjellmo; Anders Hovland; Knut Tore Lappegård
Journal:  Diseases       Date:  2018-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.